Gilead Sciences (NASDAQ:GILD) Price Target Raised to $103.00

Gilead Sciences (NASDAQ:GILD) had its target price hoisted by Royal Bank Of Canada from $100.00 to $103.00 in a research note published on Tuesday morning,MarketScreener reports. The firm currently has a sector perform rating on the biopharmaceutical company’s stock.

Several other research firms have also issued reports on GILD. JPMorgan Chase & Co. upped their price target on shares of Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a research report on Friday, October 31st. The Goldman Sachs Group increased their target price on Gilead Sciences from $110.00 to $115.00 and gave the company a “neutral” rating in a report on Thursday, January 8th. Cantor Fitzgerald restated an “overweight” rating and set a $135.00 price target on shares of Gilead Sciences in a research report on Friday, October 31st. Citigroup boosted their price objective on Gilead Sciences from $135.00 to $140.00 and gave the company a “buy” rating in a research report on Wednesday, January 7th. Finally, Wells Fargo & Company increased their price objective on Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a research note on Wednesday, December 10th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have given a Hold rating to the company. According to MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and an average price target of $133.52.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $131.14 on Tuesday. The business has a 50 day moving average of $123.76 and a 200 day moving average of $118.46. The company has a market capitalization of $162.70 billion, a price-to-earnings ratio of 20.33, a PEG ratio of 0.68 and a beta of 0.33. Gilead Sciences has a 1-year low of $92.21 and a 1-year high of $133.10. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. The business had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The business’s quarterly revenue was up 3.0% on a year-over-year basis. During the same period last year, the business earned $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, sell-side analysts predict that Gilead Sciences will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th were issued a $0.79 dividend. The ex-dividend date was Monday, December 15th. This represents a $3.16 annualized dividend and a yield of 2.4%. Gilead Sciences’s dividend payout ratio is 48.99%.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $124.83, for a total value of $1,248,300.00. Following the completion of the sale, the chief executive officer directly owned 566,698 shares in the company, valued at $70,740,911.34. This trade represents a 1.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $124.31, for a total value of $372,930.00. Following the transaction, the insider owned 103,221 shares in the company, valued at $12,831,402.51. This trade represents a 2.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 141,757 shares of company stock worth $17,569,112. 0.27% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Gilead Sciences

A number of hedge funds and other institutional investors have recently bought and sold shares of GILD. Massachusetts Financial Services Co. MA boosted its stake in Gilead Sciences by 3,763.8% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,223,304 shares of the biopharmaceutical company’s stock worth $518,368,000 after purchasing an additional 4,113,999 shares in the last quarter. Bartlett & CO. Wealth Management LLC raised its holdings in Gilead Sciences by 2.4% in the fourth quarter. Bartlett & CO. Wealth Management LLC now owns 8,161 shares of the biopharmaceutical company’s stock worth $1,002,000 after buying an additional 195 shares during the last quarter. Premier Path Wealth Partners LLC lifted its stake in shares of Gilead Sciences by 19.8% in the fourth quarter. Premier Path Wealth Partners LLC now owns 13,281 shares of the biopharmaceutical company’s stock worth $1,630,000 after buying an additional 2,194 shares in the last quarter. Triad Wealth Partners LLC grew its holdings in shares of Gilead Sciences by 51.6% during the fourth quarter. Triad Wealth Partners LLC now owns 3,501 shares of the biopharmaceutical company’s stock valued at $430,000 after buying an additional 1,192 shares during the last quarter. Finally, Spirepoint Private Client LLC increased its position in shares of Gilead Sciences by 16.4% during the fourth quarter. Spirepoint Private Client LLC now owns 76,346 shares of the biopharmaceutical company’s stock valued at $9,371,000 after acquiring an additional 10,780 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: NEJM published full Phase 3 ASCENT‑04/KEYNOTE‑D19 results showing Trodelvy (sacituzumab govitecan) + Keytruda met the primary endpoint with a ~35% PFS improvement (HR 0.65), supporting the combo as a potential new first‑line standard in PD‑L1+ metastatic TNBC — a major commercial catalyst for Gilead’s oncology franchise. NEJM ASCENT-04 Results
• Positive Sentiment: Multiple outlets (PharmaLetter) summarized the NEJM publication and reinforced the significance of the clinical data for Trodelvy’s uptake and reimbursement discussions — amplifying the immediate market reaction. PharmaLetter Trodelvy-Keytruda NEJM Coverage
• Positive Sentiment: Rothschild & Co Redburn raised its price target to $159 and kept a “buy” rating — a bullish institutional signal that supports further upside and likely contributed to buying momentum. Rothschild & Co Redburn Price Target
• Positive Sentiment: Investor commentary highlighting margin expansion and stronger free cash flow as underappreciated drivers has supported fundamental buying beyond the clinical news. Seeking Alpha on Margins & Cash Flow
• Neutral Sentiment: Market write‑ups and a Zacks note pointed out that GILD outpaced the broader market today — useful for context but largely descriptive of price action rather than new fundamental change. Zacks: Why GILD Outpaced Market
• Neutral Sentiment: Valuation and technical pieces note recent share‑price strength and improved momentum — these can attract traders but don’t alter the clinical/commercial thesis. Yahoo Valuation Check
• Negative Sentiment: Director Jeffrey Bluestone sold 5,000 shares (~$617.5k at ~$123.50), reducing his stake by ~36% — an insider sale that can prompt short‑term investor concern about timing or confidence (though insiders sell for many non‑signal reasons). SEC Form 4 — Bluestone
• Negative Sentiment: RBC’s price target (~$103, sector perform) remains well below current levels — a conservative analyst view that could limit upside if other firms adopt similar stances. RBC Price Target Note

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.